Aprea Therapeutics, Inc. (APRE) is a Biotechnology company in the Healthcare sector, currently trading at $0.94. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Valuation: APRE trades at a trailing Price-to-Earnings (P/E) of -0.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.02.
Financials: revenue is $285,759, +38.3%/yr average growth. Net income is $13M (loss), growing at +35.2%/yr. Net profit margin is -4409.2% (negative). Gross margin is 92.4% (-6.4 pp trend).
Balance sheet: total debt is $0 against $12M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 5.63 (strong liquidity). Debt-to-assets is 0%. Total assets: $16M.
Analyst outlook: 4 / 8 analysts rate APRE as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 35/100 (Fail), Future 40/100 (Partial), Income 10/100 (Fail).
